About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Rheumatoid Arthritis Clinical Trials in Philadelphia | 3,347 Studies | Clareo Health

Clinical Trials Rheumatoid ArthritisPhiladelphia

Rheumatoid Arthritis Clinical Trials in Philadelphia

Find 3,347 clinical trials for rheumatoid arthritis near Philadelphia, Pennsylvania. Connect with research centers in your area.

All Rheumatoid Arthritis trials nationwide All trials in Philadelphia

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 481-500 of 3,347 trials

RECRUITINGNA< 1 mile

TVMR With the INNOVALVE System Trial - Early Feasibility Study

NCT04919980

Study to evaluate the safety and performance of the INNOVALVE system

Mitral Valve Regurgitation (Degenerative or Functional)

Edwards Lifesciences65 participantsStarted Sep 2022

Los Angeles, California, United States • Naples, Florida, United States • Atlanta, Georgia, United States +14 more locations

RECRUITINGPhase 3< 1 mile

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

NCT05904028

Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.

Neovascular Age-related Macular Degeneration

Jaeb Center for Health Research600 participantsStarted Nov 2023

Glendale, California, United States • Loma Linda, California, United States • Oakland, California, United States +61 more locations

Rheumatoid Arthritis Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix San Antonio

Data from ClinicalTrials.govTerms

TERMINATEDPhase 2< 1 mile

Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma

NCT03076281

This randomized phase II trial studies how well metformin hydrochloride and doxycycline work in treating patients with head and neck squamous cell carcinoma that can be removed by surgery. Metformin hydrochloride may reduce the metabolic activity of cancer cells and of surrounding supportive tissue. Doxycycline may minimize toxic side effects of anti-cancer therapy. Giving metformin hydrochloride and doxycycline may work better in treating patients with head and neck squamous cell carcinoma.

LarynxLIPOral Cavity+1 more

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University7 participantsStarted Apr 2017

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 348 miles

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05067127

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.

C3GIC-MPGNC3 Glomerulopathy+9 more

Apellis Pharmaceuticals, Inc.124 participantsStarted Nov 2021

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +122 more locations

RECRUITING53 miles

Abbott Structural Heart Device Registry

NCT06590467

The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting. The Registry primarily involves gathering data from routine hospital practices and standard-of-care (SOC) procedures administered to patients. All devices used in these procedures must be commercially available to the participating site. A list of specific devices covered by the Registry are available upon request from the Sponsor. Data generated by the Registry will be used to meet regulatory requirements, such as the European Union Medical Device Regulations 2017/745, that require active post-market clinical follow-up (PMCF) for all commercially available devices.

Heart DiseasesASD - Atrial Septal DefectVSD - Muscular Ventricular Septal Defect+3 more

Abbott Medical Devices2,500 participantsStarted Aug 2024

New Brunswick, New Jersey, United States • New York, New York, United States • Pittsburgh, Pennsylvania, United States +24 more locations

TERMINATEDPhase 153 miles

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

NCT04764474

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.

Isocitrate Dehydrogenase Gene Mutation

Hutchmed46 participantsStarted Apr 2021

Orange, California, United States • Atlanta, Georgia, United States • Worcester, Massachusetts, United States +12 more locations

Active Not RecruitingPhase 161 miles

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

NCT04391049

This phase I trial studies the side effects of OBP-301 when given together with carboplatin, paclitaxel, and radiation therapy in treating patients with esophageal or gastroesophageal cancer that invades local or regional structures. OBP-301 is a virus that has been designed to infect and destroy tumor cells (although there is a small risk that it can also infect normal cells). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving OBP-301 with chemotherapy and radiation therapy may work better than standard chemotherapy and radiation therapy in treating patients with esophageal or gastroesophageal cancer.

Advanced Esophageal AdenocarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8+30 more

NRG Oncology16 participantsStarted Dec 2021

Duarte, California, United States • South Pasadena, California, United States • Upland, California, United States +14 more locations

COMPLETEDPhase 161 miles

Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

NCT03703167

The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous system lymphoma.

Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)

Memorial Sloan Kettering Cancer Center25 participantsStarted Jan 2019

Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States • Montvale, New Jersey, United States +4 more locations

Active Not RecruitingPhase 276 miles

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

NCT05588843

This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters. The study consists of 4 parallel arms (3 dose groups of SAR443122 vs placebo) to assess the efficacy and safety of SAR443122 in participants with moderate to severe UC. All participants will receive a total of 52 weeks (a 12-week induction treatment phase and a 40-week maintenance phase) of study treatment, except if treatment should be discontinued per investigator's assessment. At the end of the first 12 weeks of induction treatment, all participants in clinical response or remission will be offered study treatment up to 40 weeks and will continue with the same blinded treatment that was assigned. Participants who do not achieve clinical response or remission at the end of the initial 12 weeks induction treatment will roll over in an open-label treatment arm and will be treated with SAR443122 at the highest tested dose. In addition, participants from the maintenance treatment that lose clinical efficacy at any time up to V10/Week 40 (Week 28 of maintenance) will be offered to roll over in the open-label treatment arm with SAR443122 at the highest dose.

Colitis Ulcerative

Sanofi187 participantsStarted Nov 2022

Lancaster, California, United States • Atlanta, Georgia, United States • Evanston, Illinois, United States +103 more locations

RECRUITINGPhase 181 miles

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

NCT05929235

The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma. The main question\[s\] it aims to answer are: * Is FX-909 safe and tolerable, as a monotherapy and in combination with Pembrolizumab * What is the right dose level for patients Participants will be asked to take FX-909 daily in tablet form, or FX-909 daily and Pembrolizumab every 3 weeks, and record any outcomes from taking the drug. Participants will also be asked to return for multiple site visits for various blood tests and to collect blood and tumor samples as well as have regular CT/MRI scans.

Advanced Urothelial CarcinomaOral Drug AdministrationOpen Label

Flare Therapeutics Inc.120 participantsStarted Aug 2023

San Francisco, California, United States • New Haven, Connecticut, United States • Chicago, Illinois, United States +8 more locations

RECRUITINGPhase 382 miles

PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation

NCT05699174

This is a Phase III clinical randomized control trial to investigate differences between patient with an infected nonunion treated by PO vs. IV antibiotics. The study population will be 250 patients, 18 years or older, being treated for infected nonunion after internal fixation of a fracture with a segmental defect less than one centimeter. Patients will be randomly assigned to either the treatment (group 1) PO antibiotics for 6 weeks or the control group (group 2) IV antibiotics for 6 weeks. The primary hypothesis is that the effectiveness of oral antibiotic therapy is equivalent to traditional intravenous antibiotic therapy for the treatment of infected nonunion after fracture internal fixation, when such therapy is combined with appropriate surgical management. Clinical effectiveness will be measured as the primary outcome as the number of secondary re-admissions related to injury and secondary outcomes of treatment failure (re-infection, nonunion, antibiotic complications) within the first one year of follow-up, as defined by specified criteria and determined by a blinded data assessment panel. In addition, treatment compliance, the cost of treatment, the number of surgeries required, the type and incidence of complications, and the duration of hospitalization will be measured.

InfectionsInfected WoundNonunion of Fracture+6 more

Major Extremity Trauma Research Consortium250 participantsStarted May 2023

Indianapolis, Indiana, United States • Baltimore, Maryland, United States • Baltimore, Maryland, United States +10 more locations

RECRUITINGPhase 282 miles

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

NCT05926765

This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.

Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands

MeiraGTx, LLC276 participantsStarted Jun 2023

Gilbert, Arizona, United States • Duarte, California, United States • Miami, Florida, United States +30 more locations

COMPLETEDPhase 287 miles

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

NCT05459571

The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.

Relapsed or Refractory Large B-cell Lymphoma

Kite, A Gilead Company35 participantsStarted Aug 2022

Duarte, California, United States • Los Angeles, California, United States • Denver, Colorado, United States +13 more locations

COMPLETEDPhase 492 miles

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

NCT05452239

Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications. Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with headache, and acute medication use in adults who have migraine and MOH.

MigraineMedication Overuse Headache

H. Lundbeck A/S608 participantsStarted Jul 2022

Winter Haven, Florida, United States • Marrero, Louisiana, United States • Springfield, Missouri, United States +73 more locations

RECRUITINGNA124 miles

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women

NCT07209397

The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication. This study will include women ages 22 to 80 who have had OAB symptoms for at least 6 months. The main questions it aims to answer are: Does the MORPHEUSV device lower the number of daily episodes of accidental urine leakage caused by urgency? Does it work better than a sham (placebo) treatment? Researchers will compare the MORPHEUSV device to a sham treatment to see how well it reduces symptoms of overactive bladder. Participants will: 1) Receive one session of either the MORPHEUSV or sham treatment. 2) Track their symptoms using a diary and questionnaires 3) Return for three to six follow-up visits over 12 months. This study is being conducted at multiple clinics in the United States.

Overactive BladderOveractive Bladder (OAB)Urge Urinary Incontinence+4 more

InMode MD Ltd.202 participantsStarted Nov 2025

Palo Alto, California, United States • Washington D.C., District of Columbia, United States • Boise, Idaho, United States +6 more locations

COMPLETEDPhase 3137 miles

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

NCT04690556

This study is designed to compare the efficacy, safety and immunogenicity of LUBT010 with Lucentis® given as once monthly intravitreal injection in patients with neovascular age-related macular degeneration (AMD).

Neovascular Age-related Macular Degeneration

Lupin Ltd.600 participantsStarted Sep 2020

Beverly Hills, California, United States • Delray Beach, Florida, United States • Hagerstown, Maryland, United States +75 more locations

RECRUITINGNA183 miles

Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial

NCT06942949

The purpose of this study is to evaluate the safety and performance of the ELS to treat urinary stones. The ELS is intended to break urinary stones into small fragments that can pass during or after the procedure with less or no discomfort. Eligible patients are male or females, age 21 or older, with a single urinary stone in the ureter. Participants will undergo the ELS procedure and then be evaluated 30 days later for the presence or absence of urinary stone fragments on a CT scan. Subjects who still have stone present at Day 30 will be evaluated again at Day 60. Other outcome measures will be changes in pain, quality of life, and return to normal daily activities/work.

Kidney Calculi; Ureteral Calculi

Avvio Medical101 participantsStarted May 2025

Phoenix, Arizona, United States • Bakersfield, California, United States • La Mesa, California, United States +13 more locations

RECRUITINGPhase 2271 miles

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

NCT06660368

This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.

Relapsed or Refractory Acute Myeloid Leukemia (AML)

H. Lee Moffitt Cancer Center and Research Institute52 participantsStarted Nov 2024

Tampa, Florida, United States • Boston, Massachusetts, United States

RECRUITINGPhase 1/2339 miles

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

NCT07148128

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.

Advanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal CancerAdvanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer+2 more

Auricula Biosciences Inc.110 participantsStarted Jul 2025

Dallas, Texas, United States • San Antonio, Texas, United States • Toronto, Ontario, Canada +1 more locations

RECRUITINGPhase 2359 miles

A Study With CIT-013 in HS Patients

NCT06993233

The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS. Participants will: Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period

Hidradenitis Suppurativa (HS)

Citryll BV96 participantsStarted Oct 2025

Barrie, Canada • Calgary, Canada • London, Canada +21 more locations

PreviousPage 25 of 168Next

Other Conditions in Philadelphia

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia